Clinical Trials in Follow-Up

EDIC

Description: Epidemiology of Diabetes Interventions and Complications currently in year 30 of the trial

Status: Enrollment Closed

DAVIO 2

Description: A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

Objectives: To evaluate the efficacy and safety of two doses of the EYP-1901 Intravitreal Insert in the treatment of subjects with nAMD compared to aflibercept.

Status: Enrollment Closed

PAGODA

Pathology: Diabetic Macular Edema (DME)

Description: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema.

Study Objectives: This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).

Status: Enrollment Closed

PORTAL

Pathology: Age-related Macular Degeneration (AMD)

Description: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal).

Study Objectives: This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) 100 mg/mL with refill-exchanges administered every 24 weeks (Q24W) or every 36 weeks (Q36W) for approximately 144 weeks in participants with neovascular age-related macular degeneration who have completed either Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway) or Phase IIIb Study WR42221 (Velodrome).

Status: Enrollment Closed

VILLA

Pathology: Wet Age-Related Macular Degeneration (AMD)

Description: A prospective, observational, post-marketing surveillance study to monitor the safety of the port delivery system with ranibizumab in patients with neovascular age-related macular degenerationStudy Objectives: Verify and characterize abnormally expressed vitreous proteins in adults with full thickness macular holes (MH) versus vitreous from a floaterectomy control group.

Study Objectives: The purpose of the study is to monitor the long-term safety of patients treated with the Port Delivery System with ranibizumab (PDS), in the post-marketing setting, including evaluation of the important identified risks, potential risks, implant removal risks, and missing information associated with the PDS.

Status: Enrollment on Hold